Effect of D-003, a mixture of high molecular weight primary acids from sugar cane wax, on paracetamol-induced liver damage in rats

International Journal of Tissue Reactions

Volumn 25, Issue 3, 2003, Pages 91-98

  Mendoza, S ^a   Noa, M ^a   Mas, R ^a   Mendoza, N ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ALIPHATIC CARBOXYLIC ACID; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; D 003; LIPOPROTEIN; OCTACOSANOIC ACID; PARACETAMOL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG PURIFICATION; INFLAMMATORY INFILTRATE; LIPID PEROXIDATION; LIPOPROTEIN BLOOD LEVEL; LIVER CELL; LIVER HISTOLOGY; LIVER INJURY; LIVER NECROSIS; LIVER PROTECTION; LIVER TOXICITY; MALE; MOLECULAR WEIGHT; NONHUMAN; OXIDATION; RAT; SUGARCANE;

ACETAMINOPHEN; ADMINISTRATION, ORAL; ANIMALS; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; FATTY ACIDS; LIVER; MALE; MOLECULAR WEIGHT; PHYTOTHERAPY; PLANT PREPARATIONS; RATS; RATS, SPRAGUE-DAWLEY; SACCHARUM; WAXES;

ANIMALIA; ARUNDINARIA; SACCHARUM; SACCHARUM HYBRID CULTIVAR; SACCHARUM OFFICINARUM;

EID: 0346685839     PISSN: 02500868     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Anderson K.M., Wilson P.W.F., Odell P.M., et al. An updated coronary risk profile: A statement for health professionals. Circulation, 83, 356, 1991.
2. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results I. Reduction in the incidence of coronary heart disease. JAMA, 251(3), 351, 1984.
3. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results II. The relationship of reduction in the incidence of coronary heart disease to cholesterol lowering. JAMA, 251(3), 365, 1984.
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet, 344, 1383, 1994.
5. Tonkin A., Aylward P., Colqhoun D., et al. Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med., 339, 1349, 1998.
6. Shepherd S., Cobbe S.M., Ford I., et al. for the West of Scotland Coronary Prevention. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med., 333, 1301, 1995.
7. Downs J.R., Clearfield M., Weiss S., et al. for the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA, 279, 1615, 1998.
8. Bhatnagar D. Lipid-lowering drugs in the management of hyperlipidaemia. Pharmacol. Ther., 79, 205, 1998.
9. Farnier M., Davignon J. Current and future treatment of hyperlipidemia: The role of statins. Am. J. Cardiol., 82, 3, 1998
10. Farmer J.A., Gotto A.M. Choosing the right lipid-regulating agent: A guide to selection. Drugs, 52, 649, 1996.
11. Antilipemic agents. In: "American Formulary Hospital Service (AFHS) Drug Information, 2000." Edited by the American Society of Health-System Pharmacists Inc., Bethesda, USA, pp. 1620-1657.
12. Plaa G., Charbonnea M. Detection and evaluation of chemically induced liver injury. In: Wallace Hayes A. (Ed.). "Principles and Methods of Toxicology." Third Edition, Raven Press Ltd., New York, 1994, pp. 839-870.
13. Mitchell J.R., Jollow D.J., Potter W.Z., Davis D., Guillete J., Brodie B. Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J. Pharmacol. Exp. Ther., 187, 185, 1973.
14. Wendal A., Fevertein S. Drug induced lipid peroxidation in mice. I. Modulation by monoxigenase activity, glutathione and selenium status. Biochem. Pharmacol., 30, 2513, 1981.
15. Fairhurst S., Barber D.J., Clark B., Horton A. Studies on paracetamol-induced lipid peroxidation. Toxicology, 23, 249, 1982.
16. Harman A.W. The effectiveness of antioxidants in reducing paracetamol-induced damage subsequent to paracetamol activation. Res. Commun. Chem. Pathol. Pharmacol., 49, 215, 1985.
17. Martínez-Calva A., Campos-Apáez E., Rosales Vega A., Mourelle M. Vitamin E improves membrane lipid alterations induced by CCl4 intoxication. J. Appl. Toxicol., 4, 270, 1984.
18. González L., Marrero D., Laguna A., et al. inventors; Laboratorios Dalmer SA, assignee: Mixture of primary fatty acids of high molecular weight obtained from sugar cane wax and its pharmaceutical uses. Republic of South Africa patent 98-2744. December 30, 1998.
19. Gámez R., Mendoza S., Más R., et al. Dose-dependent cholesterol-lowering effects of D-003 on normocholesterolemic rabbits. Curr. Ther. Res. Clin. Exp., 61, 8, 2000.
20. Mendoza S., Gámez; R., Noa M., Más R., Castaño G. The effects of D-003 and policosanol on the lipid profile and endothelial cells in normocholesterolemic rabbits: A head-to-head comparison. Curr. Ther. Res. Clin. Exp., 62, 209, 2001.
21. Menéndez R., Mas R., Amor A.M., et al. Inhibition of cholesterol biosynthesis in cultured fibroblasts by D-003, a mixture of very long chain saturated fatty acids. Pharmacol. Res., 44(4), 299, 2001.
22. Molina V., Arruzazabala M.L., Carbajal D., Más R., Valdés S. Antiplatelet and antithrombotic effects of D-003. Pharmacol. Res., 42, 137, 2000.
23. Molina V., Arruzazabala M.L., Carbajal D., Más R. D-003, a potential antithrombotic compound isolated from sugar cane wax with effects on arachidonic acid metabolites. Prostag. Leuk. Ess. Fatty Acids, 67(1), 19, 2002.
24. Más R. Policosanol. Drugs of the Future, 25, 569, 2000.
25. Más R., Castaño G., Illnait J., et al. Effect of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin. Pharmacol. Ther., 65, 439, 1998.
26. Castaño G., Más R., Arruzazabala M.L., et al. Effects of policosanol, pravastatin on lipid profile, platelet aggregation, endothelemia in older hypercholesterolemic patients. Int. J. Clin. Pharm. Res., XIX, 105, 1999.
27. Fernández J.C., Más R., Castaño G., et al. Comparison of the efficacy, safety and tolerability of policosanol versus fluvastatin in elderly hypercholesterolemic women. Clin. Invest., 21, 103, 2001.
28. Mirkin A., Mas R., Martinto M., et al. Efficacy and tolerability of policosanol in hypercholesterolemic postmenopausal women. Int. J. Clin. Pharmacol. Res., XXI, 31, 2001.
29. Crespo N., Illnait J., Más R., et al. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus. Int. J. Clin. Pharmacol. Res., XIX, 117, 1999.
30. Menéndez R., Más R., Pérez Y., et al. Inhibition of rat lipoprotein lipid peroxidation by the oral administration of D-003, a mixture of very long chain saturated fatty acids. Can. J. Physiol. Pharmacol., 80 (1), 13, 2002.
31. Menéndez R., Fraga V., Amor A.M., et al. Oral administration of policosanol inhibits in vitro cooper ion-induced rat lipoprotein peroxidation. Physiol. Behav., 67, 1, 1999.
32. Menéndez R., Más R., Amor A.M., et al. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Br. J. Clin. Pharm., 50, 225, 2000.
33. Menéndez R., Más R., Amor A., et al. Effects of policosanol on the low density lipoprotein (LDL) isolated on hypercholesterolemic patients at high coronary risk to in vitro copper-mediated lipid peroxidation. A randomised, double-blinded pilot study. Curr. Ther. Res., 61, 609, 2000.
34. Gámez, R., Más, R., Noa, M., et al. Acute and subchronic oral toxicity of D-003 in rats. Toxicol. Lett., 118, 31, 2000.
35. Gámez, R., González, J.E., Rodeiro, I., et al. In vivo genotoxic evaluation of D-003, a mixture of very long-chain aliphatic acids. J. Med. Food, 4, 85, 2001.
36. Gámez, R., Rodeiro, I., Fernández, I., et al. A preliminary evaluation of the cytotoxic and genotoxic potential of D-003: A mixture of very long chain fatty acids. Teratog Carcinogen Mutag., 22 (3), 175, 2002.
37. Rodríguez, M.D., Gámez, R., González, J.E. et al. Lack of developmental toxicity of D-003: A mixture of long-chain fatty acids in rats. Food Chem. Toxicol., 41, 89, 2003.
38. Noa, M., Mendoza, S., Mendoza, N. Effect of policosanol on carbon tetrachloride-induced acute liver damage in Sprague Dawley rats. Drugs R&D, 4(1), 29, 2003.
39. 4C-induced liver acute injury in rats. Drugs Exptl. Clin. Res., 28 (5), 177, 2002.
40. González, R., Remírez, D., Rodríguez, S., et al. Hepatoprotective effects of propolis extract on paracetamol-induced liver injury in rats. Phytotherapy Res., 8, 229, 1994.
41. Coro, R.M., Borrajero, I. DIGIPAT. Un sistema cubano para morfometría de imágenes. Rev. Latinoam. Patol., 39, 9, 1996.
42. Savides, M.C., Oehme, F.W. Acetaminophen and its toxicity. J. Appl. Toxicol., 3(2), 96, 1983.
43. McLean, A.E., Nuttall, L. An in vitro model of liver injury using paracetamol treatment of liver slices and prevention of injury by some antioxidants. Biochem. Pharmacol., 27, 425, 1978.
44. Vermeulen, N.P., Bessems, J.G., Van Der Straat, R. Molecular aspects of paracetamol-induced hepatotoxicity and its mechanism-based prevention. Drug Metab. Rev., 24(3), 367, 1992.
45. Muriel, P., Garciapiña, T., Pérez-Alvarez, V., et al. Silymarin protects against paracetamol-induced lipid peroxidation and liver damage. J. Appl. Toxicol., 12(6), 439, 1992.
46. Rodríguez, S., Ancheta, O., Remírez, D., et al. Efecto protector del propóleo rojo cubano ante el daño agudo inducido en hepatocitos de roedores. Rev. CNIC, Ciencias Biológicas, 29(2), 69, 1998.
47. Nagai, H., Aoki, M., Shimazawa, T., et al. Effect of Oky-046 and ONO-3708 on liver injury in mice. Japan J. Pharmacol., 51, 191, 1989.